MedPath

Phase I trial of biweekly Carboplatin plus nab-Paclitaxel with concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer

Phase 1
Recruiting
Conditions
on-small cell lung cancer
Registration Number
JPRN-UMIN000010480
Lead Sponsor
Aomori Prefectural Central Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
18
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with T3N1. 2) Superior vena cava syndrome. 3) Contralateral hilar lymph node metastasis, malignant plueral, pericardial effusion, carcinomatous lymphangiosis. 4) Active double cancer. 5) Active infections requiring systemic treatment. 6) Severe concurrent disease (Pulmonary fibrosis or interstitial pneumonia, renal failure, hepatic failure, cerebrovascular disease, ischemic heart disease requiring treatment, arrhythmia, cardiac infarction within 6 months before enrollment, hemorrhagic peptic ulcer, poorly controlled diabetes). 7) Grade 2 or higher peripheral neuropathy. 8) Positive HBs antigen and/or HCV antibody. 9) History of Severe drug allergies. 10) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy. 11) Physician concludes that the patient's participation in this trial is inappropriate.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of dose limiting toxicities at each dose level
Secondary Outcome Measures
NameTimeMethod
Incidence and Severity of Adverse Events Treatment completion rate Response Rate 2-year survival rate Progression-free Survival Overall Survival
© Copyright 2025. All Rights Reserved by MedPath